Literature DB >> 25903044

Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.

Song-Yau Wang1, Thomas Ebert, Nadja Jaekel, Stefan Schubert, Dietger Niederwieser, Haifa Kathrin Al-Ali.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25903044     DOI： 10.1007/s00277-015-2385-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 2.  Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.

Authors:  Christopher David Swan; Thomas Gottlieb
Journal:  BMJ Case Rep       Date:  2018-07-18

3.  Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.

Authors:  Solo Traoré; Mehdi Roumila; Pirayeh Eftekhari; Hassan Farhat; Fatiha Merabet; Oumar Guira; Philippe Rousselot; Reza Azarian; Caroline Besson
Journal:  EJHaem       Date:  2020-09-19

4.  Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy.

Authors:  Ensi Voshtina; Huiya Huang; Renju Raj; Ehab Atallah
Journal:  Case Rep Hematol       Date:  2018-08-01

5.  Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis.

Authors:  Ana Colado; Melanie Genoula; Céline Cougoule; José L Marín Franco; María B Almejún; Denise Risnik; Denise Kviatcovsky; Enrique Podaza; Esteban E Elías; Federico Fuentes; Isabelle Maridonneau-Parini; Fernando R Bezares; Horacio Fernandez Grecco; María Cabrejo; Carolina Jancic; María Del Carmen Sasiain; Mirta Giordano; Romina Gamberale; Luciana Balboa; Mercedes Borge
Journal:  Blood Cancer J       Date:  2018-11-05       Impact factor: 11.037

Review 6.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

7.  Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.

Authors:  Maria Stefania Infante; Ana Fernández-Cruz; Lucia Núñez; Cecilia Carpio; Ana Jiménez-Ubieto; Javier López-Jiménez; Lourdes Vásquez; Raquel Del Campo; Samuel Romero; Carmen Alonso; Daniel Morillo; Margarita Prat; José Luis Plana; Paola Villafuerte; Gabriela Bastidas; Ana Bocanegra; Ángel Serna; Rodrigo De Nicolás; Juan Marquet; Carmen Mas-Ochoa; Raúl Cordoba; Julio García-Suárez; Alessandra Comai; Xavier Martín; Mariana Bastos-Oreiro; Cristina Seri; Belén Navarro-Matilla; Armando López-Guillermo; Joaquín Martínez-López; José Ángel Hernández-Rivas; Isabel Ruiz-Camps; Carlos Grande
Journal:  Cancer Med       Date:  2021-09-23       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.